RxDoctor Payments DataLook up a doctor →

Christopher Mocek, MD

Pain Medicine · Little Rock, ARNPI 1821050618

Payments from drug & device makers

$10,247in general payments, 2019–2025

Across 277 payments — averaging $36.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Flowonix Medical Incorporated$949
  • Biodelivery Sciences International, Inc.$944
  • Relievant Medsystems, Inc.$863
  • Nevro Corp.$837
  • Si-bone, Inc.$817
  • plus $4K from 32 others

What the payments were for

  • Speaking & faculty fees$7507%
  • Travel & lodging$2,93629%
  • Food & beverage$5,61255%
  • Entertainment$9499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,247 in reported general payments places this provider in the 80th percentile of 53 pain medicine providers in Arkansas.

See all pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,168,285
Medicare patients
918
Services billed
17,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen869$27,512
Buprenorphine69$17,836
Oxycodone Hcl1,115$16,315
BelsomraSuvorexant39$16,118
NucyntaTapentadol Hcl15$15,979
BelbucaBuprenorphine Hcl19$15,533
Xtampza ErOxycodone Myristate41$14,382
Fentanyl170$14,091
Morphine Sulfate ErMorphine Sulfate448$9,593
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen316$8,350
Hydromorphone Hcl571$7,865
Morphine Sulfate232$5,611
Hysingla ErHydrocodone Bitartrate18$5,142
Lubiprostone33$3,648
Naloxone Hcl43$2,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er$530$45,89575 claims
MerckBelsomra$186$16,11839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 53 pain medicine providers in Arkansas.

Other pain medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →